EU guideline revamp to clarify pediatric drug development rules
This article was originally published in Scrip
The European Commission is revising its 2008 guideline on pediatric investigation plans (PIPs) to bring it more into line with actual practice. The move is expected to clarify the rules in a number of areas and is seen as an important step in encouraging more companies to pursue pediatric drug development programs.
You may also be interested in...
France is exploring the use of hydroxychloroquine and lopinavir/ritonavir in COVID-19, but only in hospitalized patients and in clinical trials, and has banned all exports of the products to avoid possible shortages.
Efforts are under way in the UK on many fronts to develop new treatments and vaccines for coronavirus infection, including researching new uses of existing products and clinical trials of new vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.